A common ovarian cancer evades detection by convincing nearby immune cells to treat it as a developing fetus.
Pioneering immunotherapy drug gets new testing for early prostate cancer
Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.
Immunotherapy target identified for pediatric cancers
Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.
Beating cancer’s wildfire while the flames rage
A novel immunotherapy appears safe for use in patients with non-Hodgkin’s lymphoma. Here, a Northern California man shares his experience in the study.
Exploring the promise and challenges of cancer immunotherapy
The immune system is primed to protect the body from outside invaders, like viruses and bacteria. But can the immune system also be trained to …
Stanford researchers develop a new target for immunotherapy: sugars
Cancer immunotherapies have been big news in the past few years, particularly after former President Jimmy Carter's melanoma was successfully treated with one such immune-stimulating …